NCT01336140View on ClinicalTrials.gov

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
DRUG

Aminophylline

75 mg of intravenous aminophylline

DRUG

Placebo

Matching 0.9 Normal Saline (sterile salt water)administered intravenously.

Trial Locations (1)

60612

Rush University Medical Center, Chicago

All Listed Sponsors
collaborator

Cook County Health

OTHER_GOV

lead

Rush University Medical Center

OTHER

NCT01336140 - Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging | Biotech Hunter | Biotech Hunter